Genmab News

Genmab News

Date Title View
Oct 11, 2019
Grant of Restricted Stock Units and Warrants to Employees in Genmab
20191011_CA48_warrant grant
Oct 02, 2019
Genmab A/S has published its Articles of Association
Articles of Association - October 1, 2019 (UK)
Oct 01, 2019
Capital Increase in Genmab as a Result of Employee Warrant Exercise
191001_CA47_Warrant Exercise
Sep 26, 2019
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma
190926_CA46_CASSIOPEIA US Approval
Sep 13, 2019
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
190913_CA45_CANDOR
Sep 13, 2019
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
190913_CA44_Ofatumumab Data at ECTRIMS
Sep 09, 2019
Genmab and Tempus Enter into Strategic Collaboration Agreement
190909_i12_Tempus
Aug 30, 2019
Genmab’s Partner for Ofatumumab, Novartis, Reports that Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
190830_CA43_Ofatumumab RMS Data
Aug 22, 2019
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
190822_CA_42_ALCYONE Japan approval
Aug 21, 2019
Genmab Announces Preliminary Data to be Presented at IASLC 2019 World Conference on Lung Cancer
190821_i11_EV at WCLC
Aug 21, 2019
Genmab A/S has published its Articles of Association
Articles of Association - August 20, 2019 (UK)
Aug 20, 2019
Capital Increase in Genmab as a Result of Employee Warrant Exercise
190820_CA41_warrant exercise
Aug 19, 2019
Daratumumab Abstracts Selected for Presentation at 17th International Myeloma Workshop
190819_i10_IMW
Aug 14, 2019
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
190814_CA40_Q2 2019 Interim Report
Jul 23, 2019
Genmab A/S has published its Articles of Association
Articles of Association - July 17 2019 II (UK)
Jul 23, 2019
Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
190723_CA39_Overallotment Closing
Jul 22, 2019
Genmab A/S has published its Articles of Association
Articles of Association - 17 July 2019 UK
Jul 22, 2019
Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
190722_CA38_Closing
Jul 19, 2019
Major Shareholder Announcement
190719_CA37_Major Shareholder Blackrock Increase
Jul 19, 2019
Genmab Announces Full Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering
190719_CA36_over-allotment option
Jul 19, 2019
Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for Subcutaneous Formulation of Daratumumab
190719_i09_Dara SC EMA Submission
Jul 17, 2019
Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States
190718_CA35_Pricing
Jul 16, 2019
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2019
190716_CA34_Dara Q2 Sales
Jul 12, 2019
Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab
190712_CA33_Dara SC FDA Submission
Jul 12, 2019
Genmab and BliNK Biomedical Enter into Commercial License Agreement
190712_i08_BliNK